RecruitingNCT05028686
Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence
Sponsor
Institute for Clinical Evaluative Sciences
Enrollment
500 participants
Start Date
Feb 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.
Eligibility
Min Age: 18 YearsMax Age: 105 Years
Plain Language Summary
Simplified for easier understanding
This Canadian study uses advanced data analysis — including blood proteins, genetics, and artificial intelligence — to better predict which heart failure patients will be readmitted to hospital within 30 days of being discharged. The goal is to identify high-risk patients earlier so doctors can prevent readmissions.
**You may be eligible if...**
- You are 18 or older
- You were admitted to hospital or seen in the emergency department with heart failure
- You can give informed consent (or have a family member who can assist)
**You may NOT be eligible if...**
- You have dementia or severe cognitive difficulties that prevent communication
- You live outside Ontario
- You live in a nursing home
- You are being discharged to a long-term care or chronic care facility (not home)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo intervention
Observational cohort
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05028686
Related Trials
Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker
NCT075631531 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288653 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370638 locations
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257135 locations
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT074022391 location